ArticleCellular and molecular neurobiology2026
Effect of Esketamine Pretreatment on Necroptosis in Mice with Trigeminal Neuralgia and Anxiety-Like Behavior via the RIP1/RIP3/MLKL Pathway.
Article in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To explore the effect of esketamine (ES) pretreatment on necroptosis in mice with trigeminal neuralgia accompanied by anxiety-like behavior and its correlation with the RIP1/RIP3/MLKL signaling pathway. Thirty male C57BL/6J mice were randomized into five groups (n=6): Control, Sham, model group (PIONT), PIONT+NS, and PIONT+ES. Trigeminal neuralgia model was established by left infraorbital nerve transection. ES (10 mg/kg, i.p.) was given daily for 5 days preoperatively (preoperative pretreatment) in the PIONT+ES group before molding, and equal-volume saline was administered identically in the PIONT+NS group. Pain thresholds were measured on postoperative days 3, 7, 14 and 21. Behavioral assessments were conducted on day 19, and tissue samples were harvested on day 21. Histopathological staining, immunofluorescence, qPCR, Western blot, ELISA and molecular docking were further performed for subsequent analyses. PIONT group showed reduced pain thresholds, anxiety-like behaviors, neuronal degeneration, decreased dendritic spine density, elevated TNF-α, and upregulated RIP1/RIP3/MLKL (all P<0.05). ES pretreatment prevented the development of these pathological alterations, with improved neuropathology, reduced TNF-α/RIP1/RIP3/MLKL levels, and increased spine density (P<0.05). Molecular docking showed ES binds RIP1/RIP3/MLKL/TNF-α with energies -5.46, -5.10, -5.94, -7.36 kcal/mol. ES pretreatment prevents the development of trigeminal neuralgia and anxiety-like behaviors in mice, which is associated with suppression of necroptosis-related signaling.
Indexed as
Identifiers
42918931What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.